Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ3108MR)

This product GTTS-WQ3108MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Neuroblastoma research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 1
Species	Chimeric
RefSeq	NM_001276468.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	2583
UniProt ID	Q00973

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3108MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ7224MR	IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A))	mRNA	FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ5252MR	IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, Pseudo-UTP, 30 nt-poly(A))	mRNA	CB-6
GTTS-WQ4669MR	IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	BMS-986089
GTTS-WQ1224MR	IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	ABR-217620
GTTS-WQ5554MR	IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	CDP7657
GTTS-WQ1784MR	IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	ADCT-301(unconjugated)
GTTS-WQ3843MR	IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	BCD-054
GTTS-WQ9947MR	IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	KBSA301

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST